| Simple and efficient site-directed mutagenesis using two single-primer reactions in parallel to generate mutants for protein structure-function studies O Edelheit, A Hanukoglu, I Hanukoglu BMC biotechnology 9, 1-8, 2009 | 429 | 2009 |
| Epithelial sodium channels (ENaC) are uniformly distributed on motile cilia in the oviduct and the respiratory airways Y Enuka, I Hanukoglu, O Edelheit, H Vaknine, A Hanukoglu Histochemistry and cell biology 137, 339-353, 2012 | 129 | 2012 |
| Novel mutations in epithelial sodium channel (ENaC) subunit genes and phenotypic expression of multisystem pseudohypoaldosteronism O Edelheit, I Hanukoglu, M Gizewska, N Kandemir, ... Clinical Endocrinology 62 (5), 547-553, 2005 | 100 | 2005 |
| Renin–aldosterone response, urinary Na/K ratio and growth in pseudohypoaldosteronism patients with mutations in epithelial sodium channel (ENaC) subunit genes A Hanukoglu, O Edelheit, Y Shriki, M Gizewska, N Dascal, I Hanukoglu The Journal of steroid biochemistry and molecular biology 111 (3-5), 268-274, 2008 | 70 | 2008 |
| Subclonal therapy by two EGFR TKIs guided by sequential plasma cell-free DNA in EGFR-mutated lung cancer N Peled, LC Roisman, B Miron, R Pfeffer, RB Lanman, M Ilouze, A Dvir, ... Journal of Thoracic Oncology 12 (7), e81-e84, 2017 | 53 | 2017 |
| Truncated beta epithelial sodium channel (ENaC) subunits responsible for multi-system pseudohypoaldosteronism support partial activity of ENaC O Edelheit, I Hanukoglu, Y Shriki, M Tfilin, N Dascal, D Gillis, A Hanukoglu The Journal of Steroid Biochemistry and Molecular Biology 119 (1-2), 84-88, 2010 | 38 | 2010 |
| Identification of the roles of conserved charged residues in the extracellular domain of an epithelial sodium channel (ENaC) subunit by alanine mutagenesis O Edelheit, I Hanukoglu, N Dascal, A Hanukoglu American Journal of Physiology-Renal Physiology 300 (4), F887-F897, 2011 | 32 | 2011 |
| Conserved charged residues at the surface and interface of epithelial sodium channel subunits–roles in cell surface expression and the sodium self‐inhibition response O Edelheit, R Ben‐Shahar, N Dascal, A Hanukoglu, I Hanukoglu The FEBS Journal 281 (8), 2097-2111, 2014 | 29 | 2014 |
| Not all RAS mutations created equal: Functional and clinical characterization of 80 different KRAS and NRAS mutations. JM Loree, B Miron, V Holla, MJ Overman, AAL Pereira, M Lam, VK Morris, ... Journal of Clinical Oncology 35 (15_suppl), 3589-3589, 2017 | 13 | 2017 |
| Revisited analysis of a SHIVA 01 trial cohort using functional mutational analyses successfully predicted treatment outcome M Kamal, G Tarcic, S Dureau, O Edelheit, Z Barbash, C Lecerf, C Morel, ... Molecular Oncology 12 (5), 594-601, 2018 | 6 | 2018 |
| Functional mutational analysis to assess the oncogenic activity of variant of uncertain significance (VUS) detected in patients included in the SHIVA trial G Tarcic, M Kamal, O Edelheit, Z Barbash, M Vidne, B Miron, C Callens, ... European Journal of Cancer 1 (69), S6-S7, 2016 | 2 | 2016 |
| Functional characterization of mutations and their interaction using the novel functional annotation for cancer treatment (FACT) platform B Miron, N Peled, Z Barbash, O Edelheit, M Vidne, R Sharivkin, G Tarcic Annals of Oncology 27, vi404, 2016 | 1 | 2016 |
| Functional profiling of oncogenic mutations in lung cancer patients (NCT02274025)-interim results B Miron, N Peled, G Tarcic, Z Barbash, O Edelheit, M Vidne, MR Kramer Annals of Oncology 27, vi412, 2016 | 1 | 2016 |
| Retrospective analysis of a SHIVA01 trial cohort using functional mutational analysis successfully predicted treatment outcome G Tarcic, C Le Tourneau, M Kamal, O Edelheit, Z Barbash, M Vidne, ... Annals of Oncology 28, v450-v451, 2017 | | 2017 |
| Novel platform to profile variants of uncertain significant (VUS) with preliminary retrospective clinical validation in non-small cell lung cancer (NSCLC) B Miron, G Tarcic, O Edelheit, N Burck, M Vidne, L Roisman, N Peled CANCER RESEARCH 77, 2017 | | 2017 |
| Abstract LB-041: Novel platform to profile variants of uncertain significant (VUS) with preliminary retrospective clinical validation in non-small cell lung cancer (NSCLC) B Miron, G Tarcic, O Edelheit, N Burck, M Vidne, L Roisman, N Peled Cancer Research 77 (13_Supplement), LB-041-LB-041, 2017 | | 2017 |
| Functional characterization of variants of unknown significance (VUS) in patients and their responsiveness to targeted therapy drugs (TTD) G Tarcic, CM Walko, HL McLeod, JK Hicks, Z Barbash, O Edelheit, ... Annals of Oncology 27, vi403, 2016 | | 2016 |
| Functional characterization of VUS mutations found in patients' cell-free circulating tumor DNA (ctDNA) using Precision Cancer Analysis System (PCAS). G Tarcic, DA Simon, M Jacobstein, RB Lanman, M Vidne, Z Barbash, ... Journal of Clinical Oncology 34 (15_suppl), 11576-11576, 2016 | | 2016 |
| Functional profiling of oncogenic mutations in lung cancer patients (NCT02274025): Interim results. G Tarcic, N Peled, Z Barbash, O Edelheit, M Vidne, MR Kramer Journal of Clinical Oncology 34 (15_suppl), e20066-e20066, 2016 | | 2016 |
| Functional characterization of non-V600 BRAF mutations and their response to Trametinib (Tram). RJ Sullivan, Z Barbash, O Edelheit, M Vidne, JA Sosman, K Flaherty, ... Journal of Clinical Oncology 34 (15_suppl), 9537-9537, 2016 | | 2016 |
Israel Hanukoglu, Ph.D.Professor of Biochemistry and Molecular Biology, IsraelVerified email at ariel.ac.il
